Psoriatic arthritis (PsA) is a chronic inflammatory condition involving the spine, enthesis and peripheral joints, which is associated with psoriasis. PsA therapy varies from use of NSAIDs to disease-modifying anti-rheumatic agents (DMARDs). However, their use can represent a limitation in patients with concomitant hepatitis C virus (HCV) infection. In the last few decades, anti-TNF-α therapy has opened new horizons in the treatment of PsA. Hence, the purpose of this review is to explore the efficacy and safety of anti-TNF-α agents in PsA and concomitant HCV infection.
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection / Caso, Francesco; Cantarini, Luca; Morisco, Filomena; DEL PUENTE, Antonio; Ramonda, Roberta; Fiocco, Ugo; Lubrano, Ennio; Peluso, Rosario; Caso, Paolo; Galeazzi, Mauro; Punzi, Leonardo; Scarpa, Raffaele; Costa, Luisa. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 15:5(2015), pp. 641-50-650. [10.1517/14712598.2015.1011616]
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection
CASO, FRANCESCO;MORISCO, FILOMENA;DEL PUENTE, ANTONIO;PELUSO, ROSARIO;SCARPA, RAFFAELE;COSTA, LUISA
2015
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory condition involving the spine, enthesis and peripheral joints, which is associated with psoriasis. PsA therapy varies from use of NSAIDs to disease-modifying anti-rheumatic agents (DMARDs). However, their use can represent a limitation in patients with concomitant hepatitis C virus (HCV) infection. In the last few decades, anti-TNF-α therapy has opened new horizons in the treatment of PsA. Hence, the purpose of this review is to explore the efficacy and safety of anti-TNF-α agents in PsA and concomitant HCV infection.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
